Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

NCT02892734 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

HER2/Neu Negative
Recurrent Inflammatory Breast Carcinoma
Stage IV Breast Cancer
Stage IV Inflammatory Breast Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]